SU873879A3 - Способ получени производных бензимидазола или их солей - Google Patents

Способ получени производных бензимидазола или их солей Download PDF

Info

Publication number
SU873879A3
SU873879A3 SU802867805A SU2867805A SU873879A3 SU 873879 A3 SU873879 A3 SU 873879A3 SU 802867805 A SU802867805 A SU 802867805A SU 2867805 A SU2867805 A SU 2867805A SU 873879 A3 SU873879 A3 SU 873879A3
Authority
SU
USSR - Soviet Union
Prior art keywords
methyl
hydrogen
compound
salts
methoxy
Prior art date
Application number
SU802867805A
Other languages
English (en)
Inventor
Кристер Юнггрен Ульф
Эрик Сестранд Свен
Original Assignee
Аб Хессле(Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20334608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SU873879(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аб Хессле(Фирма) filed Critical Аб Хессле(Фирма)
Application granted granted Critical
Publication of SU873879A3 publication Critical patent/SU873879A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

(54) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ БЕНЗИМИДАЗОЛА ИЛИ ИХ СОЛЕЙ Изобретение относитс  к получению но вых производных бензимицазола, в частности к способу получени  производных бензимицазола общей формулы 1 JKT 9Бз,вЛч.5 где Ц в положении 4 означает воцороц или метил, в положении 5- - водород , Метил, метокси, ацетил, карбометокси, карбоэтокси шга хлор; I,j,Rj,Rj, водород или метвл; 1 -водород, метвл, метокси, этокси или 2 -метоксиэтоксй,причем Pg, Н, R могут быть одинаковы шга.различйы, одновременно не означают вбаород, и если два из радикалов Rj, Нд, Rj означают во дород, то третий не означает метил, юга их солей, обладающих тормоз щим выделение кислоты желудочного сока действием . Известен способ получени  2-сульфиниппроизводных бензимидазола, обладающих тормоз щей выделение кислоты желудочного сока активностью, путем окислени  соответствующих 2-меркаптопроиЗводных бе нзимиаазола,например м-хлоранабен- зойнойкиспогой.гипохлоридом натри  и ap.Lll Цель изобретени  - получение новых производных бензимицазола общей формулы 1, обладающих улучшенными по сравнению с известными соей,иненнммигвг йст ами. Поставленна  цель достигаетс  тем, что согласно способу получени  производных бензимидазолд формулы соединение общей. формулы li. I где R и и. . имеют указанные значени , подвергают взаимодейст-вию с соединением общей формулы ;RU где F, F, Rj, и R имеют указанные значени , с послеауюшим окислением получаемого при этом соеаинени  и выцепе кием целевого. продукта в свобопном виде шга в вице соли. П р и м е р 1. Смесь из 23,4 г 3,4,5-триметилпириаил-2 -меркаптомурач вьиной кислоты и 16,6 г 4-ацетил 5-метил-о-фениленциамина в 1ОО мл 4 и. хлористовоцородной кислоты кип т т в течение 4О мин. Смесь охлаждают и нейтрализуют аммиаком. Затем нейтральный раствор экстрагируют этилацетатом . Органическую фазу обрабатывают а тивным углем и упаривают в вакууме. Остаток рдаствор ют в ацетоне и затем добавл ют эквивалент концентрированной хлористоводородной кислоты. Оса дающийс  гидрохлорид, охлаждают фильтруют и перекристаллизовывают из абсолю ного этанола и простого эфира. Получают 6,5 г гиарохлорива 2-{ 3,4,5-тРиметилпиТаблица 1 ридил)-2-метилмеркапто-5-ацетил-5-метилбензимидазола .Это соединение раствор ют в хлороформе и подвергают окислению м-хлорнадбензойной кислотой при , Осаждаемую м-хлорбензойную кислоту фильтруют и фильтрат разбавл ют, хлористым метиленом , промывают раствором карбоната натри , сушат над сульфатом натри  и упаривают в вакууме. После разбавлени  ацетонитрилом остаток кристаллизуетс . После перекристаллизации из ацетонитрила получают 2- (3,4,5-триметилпирнаил-2-метилсульфинш: )-5-ацетил-6-метилбензимиаазола с т.пл. i90°C, Примеры 2.30. Аналогично примеру 1 .получают, соединени , сведенные в табл. 1
Продолжение табл. 1
Биологические опыты. Дл  определени  . степени торможени  вы целени  кислоты желудочного сока провод т опыты на нб- анестезированных собаках с фистулами, введенными в желудок и двенадцатиперстную кишку. При этом по фистуле, введенной в двенадцатиперстную кишку, подают исследуемые соединени . В начале опытов собакам дают воду в течение 18 ч. Затем собакам делают подкожную инфузию пентагастрина в количестве 1-4 нмоль/ /кг/ч в течение 6-7 ч. Каждые 30 мин собирают пробы желудочного сока. Аликвотную долю каждой пробы титруют ОД н.
цент торможени  по сравнению с контрольными опытами. Максимальна  степень торможени  указана в табл. 2. Исследуемые соединени  (в виде суспензии в 0,5% ме- тилцеллюлозы) ввод т в двенадцатиперстную кишку в дозах 4-2О ммоль/кг после достижени  посто нного уровн  секретного ответа на дачу пентагастрина,
В опытах примен ют предлагаемые и известные соединени , указанные в табл.2.
Ч
Y f ciH-LJ
1- N
«

Claims (1)

  1. Првмвчавве:х- взвествое соецивбвие 1 Формула изобретени  Способ получени  производных бенэ имицазола обшей формулы 1 где 1 в пол или метил, в 1 тил, метокси, боэтокси или хлор; . Э 5 6 водород или метил; Кд водород, метил, метокси, этокси или 2-метоксиэтокси, причем % могут быть одинаковы или различны,, одновременно не означают водород, и если два из радикалов К-, 1, Rg- означают в дород, то третий не означает метил, или 9 их солей, отличающийс что соединение общей формулы 11 is, :кНг где К и f(fi имеют указанные значени , подвергают взаимодействию с соединением общей формулы 1ПНц. HOO(i CH-4jjJ . fде Rj R г и F, имеют указанные значени , с последующим окислением получаемого при этом соединени  и выделением целевого продукта в свободном виде или в виде соли. Источники информации, прин тые во внимание при экспертизе 1. Авторское свидетельство СССР № 602118, кл. С O7D 401/12, 1975.
SU802867805A 1978-04-14 1980-01-18 Способ получени производных бензимидазола или их солей SU873879A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7804231A SE7804231L (sv) 1978-04-14 1978-04-14 Magsyrasekretionsmedel

Publications (1)

Publication Number Publication Date
SU873879A3 true SU873879A3 (ru) 1981-10-15

Family

ID=20334608

Family Applications (4)

Application Number Title Priority Date Filing Date
SU792751500A SU895292A3 (ru) 1978-04-14 1979-04-13 Способ получени производных бензимидазола или их солей
SU802867805A SU873879A3 (ru) 1978-04-14 1980-01-18 Способ получени производных бензимидазола или их солей
SU802870598A SU878196A3 (ru) 1978-04-14 1980-01-18 Способ получени производных бензимидазола или их солей
SU802870599A SU873880A3 (ru) 1978-04-14 1980-01-18 Способ получени производных бензимидазола или их солей

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SU792751500A SU895292A3 (ru) 1978-04-14 1979-04-13 Способ получени производных бензимидазола или их солей

Family Applications After (2)

Application Number Title Priority Date Filing Date
SU802870598A SU878196A3 (ru) 1978-04-14 1980-01-18 Способ получени производных бензимидазола или их солей
SU802870599A SU873880A3 (ru) 1978-04-14 1980-01-18 Способ получени производных бензимидазола или их солей

Country Status (25)

Country Link
US (3) US4255431A (ru)
EP (1) EP0005129B1 (ru)
JP (2) JPS6034956B2 (ru)
AT (2) AT389995B (ru)
BG (1) BG61492B2 (ru)
CA (1) CA1127158A (ru)
CS (1) CS261851B2 (ru)
CY (1) CY1232A (ru)
DD (1) DD142882A5 (ru)
DE (1) DE2960293D1 (ru)
DK (1) DK150510C (ru)
FI (1) FI65067C (ru)
HK (1) HK15284A (ru)
HU (1) HU179022B (ru)
IE (1) IE48370B1 (ru)
LT (1) LT2274B (ru)
LU (2) LU88305I2 (ru)
MY (1) MY8500074A (ru)
NL (2) NL930074I2 (ru)
NO (5) NO152216C (ru)
NZ (1) NZ190203A (ru)
SE (1) SE7804231L (ru)
SG (1) SG63383G (ru)
SU (4) SU895292A3 (ru)
ZA (1) ZA791586B (ru)

Families Citing this family (372)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
JPS58135881A (ja) * 1981-11-05 1983-08-12 ビク−グルデン・ロムベルク・ヘミツシエ・フアブリク・ゲゼルシヤフト・ミト・ベシユレンクテル・ハフツング 置換ベンズイミダゾ−ル類、その製造方法と利用、およびこれを含む医薬
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
DE3216843C2 (de) * 1982-05-05 1986-10-23 Ludwig Heumann & Co GmbH, 8500 Nürnberg 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL71664A (en) * 1983-05-03 1987-11-30 Byk Gulden Lomberg Chem Fab Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
HU191756B (en) * 1983-05-03 1987-04-28 Byk Gulden Lomberg Chem Fab Process for preparing new fluoro-alkoxy-benzimidazole derivatives
CA1259070A (en) * 1983-07-01 1989-09-05 Upjohn Company (The) Substituted 2-¬monoannelated(3,4-,4,5-, and 5,6-)- pyridylalkylenesulfinyl|-benzimidazoles
US5077407A (en) * 1983-07-01 1991-12-31 The Upjohn Company Substituted 2-[monoannelated (3,4-,4,5-, and 5,6-) pyridylalkylenesulfinyl]benzimidazoles
DE3333314A1 (de) * 1983-09-15 1985-03-28 Hoechst Ag, 6230 Frankfurt Substituierte pyrido(1,2-c)imidazo(1,2-a)benzimidazole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
ZW4585A1 (en) * 1984-04-19 1985-11-20 Hoffmann La Roche Imidazole derivatives
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0174717B1 (en) * 1984-07-06 1992-01-22 FISONS plc Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS6150979A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4619997A (en) * 1984-09-06 1986-10-28 The Upjohn Company Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents
KR890000387B1 (ko) * 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
SE8405588D0 (sv) * 1984-11-08 1984-11-08 Haessle Ab New compounds
DK585485A (da) * 1984-12-18 1986-08-08 Utsuka Pharm Co Ltd Tetrahydroquinolinderivat, imidazopyridinderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat med mindst en saadan forbindelse
FI861772A (fi) * 1985-05-07 1986-11-08 Chemie Linz Ag Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning.
US5869513A (en) * 1985-05-24 1999-02-09 G. D. Searle & Co. 2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines
EP0204215B1 (en) 1985-05-24 1993-08-11 G.D. Searle & Co. 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
US4738975A (en) * 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
AR243167A1 (es) 1985-08-24 1993-07-30 Hoechst Ag Procedimiento para la preparacion de toluidinas sustituidas.
JPS6261978A (ja) * 1985-09-12 1987-03-18 Otsuka Pharmaceut Co Ltd 5−フルオロ−1h−ベンズイミダゾ−ル誘導体
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
DE3777855D1 (de) 1986-02-20 1992-05-07 Hoechst Ag Substituierte thienoimidazol-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer.
WO1987005296A1 (en) * 1986-03-07 1987-09-11 Pfizer Inc. 2-[(2-pyridyl)methylsulfinyl]thienoimidazoles and related compounds as antiulcer agents
EP0239306B1 (en) 1986-03-27 1993-06-02 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4687775A (en) * 1986-07-17 1987-08-18 G. D. Searle & Co. 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
US4772619A (en) * 1986-07-17 1988-09-20 G. D. Searle & Co. [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines
US4721718A (en) * 1986-08-18 1988-01-26 G. D. Searle & Co. 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers
CA1256109A (en) * 1986-09-10 1989-06-20 Franz Rovenszky Process for the preparation of derivatives of 4, 5-dihydrooxazoles
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
ATE103912T1 (de) * 1986-11-13 1994-04-15 Eisai Co Ltd Pyridin-derivate, deren pharmazeutische zusammenstellungen, deren anwendung fuer die herstellung von arzneimitteln mit therapeutischem oder vorbeugendem wert und verfahren zu deren herstellung.
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SE8604998D0 (sv) 1986-11-21 1986-11-21 Haessle Ab Novel pharmacological compounds
NZ222495A (en) 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
DE3639926A1 (de) * 1986-11-22 1988-06-01 Hoechst Ag Substituierte thienoimidazoltoluidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
FI91754C (fi) * 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
JPS63230633A (ja) * 1987-03-19 1988-09-27 Nippon Chemiphar Co Ltd 胃腸の細胞保護剤
DE3719783A1 (de) * 1987-06-13 1988-12-22 Hoechst Ag Verfahren zur herstellung von 5-phenylsulfinyl-1h-2-(methoxycarbonylamino)- benzimidazol
FI96860C (fi) * 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
JP2718945B2 (ja) * 1987-06-17 1998-02-25 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
DE3723327A1 (de) * 1987-07-15 1989-02-02 Hoechst Ag Substituierte thienoimidazol-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer, magenschutzmittel sowie als medikament gegen intestinale entzuendungen
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
EP0425505B1 (en) * 1988-06-30 1993-03-17 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AU4057189A (en) * 1988-08-23 1990-03-23 Aktiebolaget Hassle Treatment of glaucoma and related disorders in the human eye with pyridinylmethyl (sulfinyl or thio)benzimidazoles
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
WO1990003373A1 (en) * 1988-09-20 1990-04-05 Hisamitsu Pharmaceutical Co., Inc. NOVEL DIBENZ[b,e]OXEPIN DERIVATIVES
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
EG19302A (en) * 1988-12-22 1994-11-30 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
GB2239453A (en) * 1989-11-27 1991-07-03 Haessle Ab Omeprazole
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5274099A (en) * 1989-12-20 1993-12-28 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
BR9106309A (pt) 1990-04-04 1993-04-20 Chiron Corp Combinacao de antigenos sinteticos de hepatite c viral (hcv),processo de detectar anticorpos para o virus da hepatite c e estojo para realizar teste
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
ES2140391T3 (es) * 1990-06-20 2000-03-01 Astra Ab Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
US5061805A (en) * 1990-08-10 1991-10-29 Reilly Industries, Inc. Process for preparing 2-methyl-3,5-dialkylpyridines by dealkylation with sulfur
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
CA2053216C (en) 1990-10-12 2003-04-08 Michel L. Belley Saturated hydroxyalkylquinoline acids as leukotriene antagonists
DE69132082T2 (de) * 1990-10-17 2000-08-31 Takeda Chemical Industries, Ltd. Pyridin-Derivate, Verfahren zu deren Herstellung und Anwendung
ES2026761A6 (es) * 1990-10-31 1992-05-01 Genesis Para La Investigacion Procedimiento de obtencion del omeprazol.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
HUT71885A (en) * 1992-07-08 1996-02-28 Monsanto Co Process for preparing a composition containing benzimidazoles for treatment stomach ulcer in swine
US5589491A (en) * 1992-07-28 1996-12-31 Astra Aktiebolag Injection and injection kit containing omeprazole and its analogs
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
TW280770B (ru) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
KR960705811A (ko) * 1993-10-29 1996-11-08 고오야 다다시 피리딘 화합물 및 그의 약학적 용도[pyridine compound and medicinal use thereof]
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US5502195A (en) * 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
SK283626B6 (sk) 1994-07-08 2003-10-07 Astrazeneca Ab Multijednotková tabletovaná dávková forma, spôsob jej prípravy a jej použitie
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
JP3015702B2 (ja) * 1995-02-21 2000-03-06 株式会社アラクス イミダゾール誘導体及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれらを有効成分とする抗潰瘍剤
JP3046924B2 (ja) * 1995-03-27 2000-05-29 株式会社アラクス イミダゾリン誘導体又はそれらの可能な互変異性体及びそれらの製造方法並びにそれらを有効成分とする創傷治療薬
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
HU227566B1 (en) * 1995-09-21 2011-08-29 Pharma Pass Llc Acid-labile pharmaceutical composition containing omeprazole and process for its preparation
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
AU1538397A (en) * 1996-02-06 1997-08-28 Pdi-Research Laboratories, Inc. Synthesis of omeprazole-type pyridine derivatives and intermediates thereof
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5625069A (en) * 1996-07-22 1997-04-29 Development Center For Biotechnology Process for preparing 2-cyano-3,5-dimethyl-4-methoxypyridine
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CA2204580A1 (en) * 1997-05-06 1998-11-06 Michel Zoghbi Synthesis of pharmaceutically useful pyridine derivatives
US6437139B1 (en) 1997-05-06 2002-08-20 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
KR100463031B1 (ko) * 1997-05-26 2005-04-06 동아제약주식회사 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
JP2002510293A (ja) * 1997-05-30 2002-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 抗潰瘍剤として新規なベンゾイミダゾール誘導体、それらの製造方法、及びそれらを含有する薬学的組成物
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6313303B1 (en) * 1997-07-11 2001-11-06 Eisai Co., Ltd. Process for the preparation of pyridine derivatives
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
AU9067198A (en) 1997-07-25 1999-02-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US7230014B1 (en) * 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU751066B2 (en) 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
DE19754324A1 (de) * 1997-12-08 1999-06-10 Byk Gulden Lomberg Chem Fab Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6159968A (en) * 1998-01-15 2000-12-12 University Of Cincinnati Activation of chloride channels for correction of defective chloride transport
US6350876B2 (en) 1998-01-26 2002-02-26 Kuraray Co., Ltd. 4-chloro-3,5-dimethyl-2-sulfonyl pyridines
KR100396431B1 (ko) * 1998-01-26 2003-09-02 가부시키가이샤 구라레 2-술포닐피리딘 유도체 및 2-[((2-피리딜)메틸)티오]-1h-벤즈이
IT1299198B1 (it) * 1998-03-05 2000-02-29 Nicox Sa Sali nitrati di farmaci antiulcera
KR100554924B1 (ko) 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
US6303787B1 (en) 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
AU4387799A (en) * 1998-06-26 2000-01-17 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
ES2192394T3 (es) 1998-08-10 2003-10-01 Winston Pharmateuticals Llc Profarmacos de inhibidores de la bomba de protones.
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
US6191148B1 (en) 1998-08-11 2001-02-20 Merck & Co., Inc. Omerazole process and compositions thereof
PT1105105E (pt) 1998-08-12 2006-07-31 Altana Pharma Ag Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
AU1054899A (en) * 1998-11-06 2000-05-29 Dong-A Pharmaceutical Co., Ltd. Method of preparing sulfide derivatives
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
IL146504A0 (en) 1999-06-07 2002-07-25 Byk Gulden Lomberg Chem Fab Pharmaceutical compositions containing an acid-labile active compound and processes for the preparation thereof
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
EP1206263A1 (en) * 1999-08-26 2002-05-22 aaiPharma Inc. Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CA2382867A1 (en) * 1999-08-26 2001-03-01 Applied Analytical Industries, Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DE19951960C2 (de) * 1999-10-28 2002-06-27 Gruenenthal Gmbh Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
AU2583901A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
KR20030059318A (ko) 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
CA2430816C (en) 2000-12-07 2012-05-15 Altana Pharma Ag Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
EP1341528B1 (en) 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient
KR20040029966A (ko) 2001-02-02 2004-04-08 테바 파마슈티컬 인더스트리즈 리미티드 치환된 2-(2-피리딜메틸)설피닐-1h-벤즈이미다졸
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
MXPA03011017A (es) * 2001-06-01 2005-04-29 Pozen Inc Composiciones farmaceuticas para la entrega coordinada de nsaids.
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
AU2002332178B2 (en) * 2001-09-18 2005-12-08 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DK1459737T3 (da) 2001-10-17 2013-01-02 Takeda Pharmaceutical Granulat indeholdende syreustabilt kemisk middel i stor mængde
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
ES2286408T3 (es) 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
BR0309093A (pt) 2002-04-09 2005-02-09 Flamel Tech Sa Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
KR100788778B1 (ko) * 2002-07-19 2007-12-27 윈스턴 파마슈티컬즈, 엘엘씨 벤즈이미다졸 유도체 및 이들의 프로톤 펌프 억제제의프로드럭으로서의 이용
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
SE0203092D0 (en) * 2002-10-18 2002-10-18 Astrazeneca Ab Method for the synthesis of a benzimidazole compound
FR2845915B1 (fr) 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
BR0315574A (pt) * 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
KR101062806B1 (ko) 2002-12-06 2011-09-07 니코메드 게엠베하 광학적으로 순수한 활성 화합물의 제조 방법
EP1575941B1 (en) 2002-12-06 2012-04-11 Nycomed GmbH Process for preparing (S)-pantoprazole
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
JP2006514108A (ja) * 2002-12-19 2006-04-27 テバ ファーマシューティカル インダストリーズ リミティド パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
EP1601667A2 (en) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
WO2004087702A2 (fr) * 2003-03-28 2004-10-14 Sidem Pharma Procede de preparation enantioselective de derives de sulfoxydes.
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
US7683177B2 (en) * 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
BRPI0412590A (pt) * 2003-07-15 2006-09-19 Allergan Inc processo para preparação de pró-drogas isomericamente puras de inibidores de bomba de próton
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
AU2004268383A1 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
RU2006117793A (ru) * 2003-10-24 2007-12-10 Иммунэйд Пти Лтд. (Au) Способ лечения
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005077936A1 (en) 2004-02-11 2005-08-25 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides with high purity
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
EP1715861A2 (en) * 2004-02-18 2006-11-02 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US20080287502A1 (en) * 2004-03-30 2008-11-20 Dermatrends, Inc. Transdermal Administration of Proton Pump Inhibitors
DK1740571T3 (da) 2004-04-28 2009-11-02 Hetero Drugs Ltd Fremgangsmåde til fremstilling af pyridinylmethyl-1H-benzimidazolforbindelser i enantiomerisk beriget form eller som enkelte enantiomerer
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
PT1748998E (pt) 2004-05-28 2010-03-24 Hetero Drugs Ltd Novo processo de síntese estereoselectiva de sulfóxidos de benzimidazol
CA2568652A1 (en) * 2004-06-02 2005-12-15 Altana Pharma Ag Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN102775388B (zh) 2004-09-13 2016-01-20 武田药品工业株式会社 氧化化合物的制备方法和制备装置
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR20070109985A (ko) 2004-11-22 2007-11-15 아나디스 리미티드 생물활성 조성물
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1891043A1 (en) 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
WO2007004236A2 (en) 2005-07-04 2007-01-11 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
JP5289951B2 (ja) * 2005-07-26 2013-09-11 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 同位体置換されたパントプラゾール
NZ565078A (en) * 2005-07-26 2010-03-26 Nycomed Gmbh Deuterated proton pump inhibitors such as omeprazole
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃H+,K+−ATPaseの重水素化阻害剤
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
JP2009518394A (ja) 2005-12-05 2009-05-07 アストラゼネカ・アクチエボラーグ エソメプラゾールの非塩形態の新規の製造方法
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US7786309B2 (en) 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EP3628307A1 (en) 2006-12-22 2020-04-01 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
EP2186807B1 (en) * 2007-02-21 2015-01-07 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
CA2679741A1 (en) * 2007-03-15 2008-09-18 Sun Pharma Advanced Research Company Ltd. Novel prodrugs
ATE534643T1 (de) * 2007-06-07 2011-12-15 Aurobindo Pharma Ltd Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
EP2181106A1 (en) * 2007-07-17 2010-05-05 Ranbaxy Laboratories Limited Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate
WO2009066317A2 (en) * 2007-08-20 2009-05-28 Macleods Pharmaceuticals Limited Process for the preparation of pantoprazole sodium
WO2009047775A2 (en) 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN101450939B (zh) * 2007-12-05 2013-06-19 沈阳药科大学 新型苯并咪唑类化合物
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
SG10201403986UA (en) * 2008-04-15 2014-10-30 Merck Sharp & Dohme High Density Compositions Containing Posaconazole And Formulations Comprising The Same
CA2720851A1 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
KR101044880B1 (ko) * 2008-06-12 2011-06-28 일양약품주식회사 항궤양제 화합물의 합성에 유용한 중간체의 제조방법
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
EP2350044A4 (en) * 2008-10-10 2012-06-06 Celtaxsys Inc PROCESS FOR INTRODUCTION OF NEGATIVE CHEMOTAXIS
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CA2763373C (en) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methods and systems for determining preferred times for administering therapy to treat diseases
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
US9623622B2 (en) 2010-02-24 2017-04-18 Michael Baines Packaging materials and methods
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
US20140343104A1 (en) 2011-08-26 2014-11-20 National University Corporation Nagoya University Osteogenesis promoter and use thereof
EP2862569A1 (en) 2011-09-09 2015-04-22 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
ES2906114T3 (es) 2013-01-15 2022-04-13 Ironwood Pharmaceuticals Inc Forma de dosificación oral gastrorretentiva de liberación sostenida de un secuestrante de ácidos biliares
BR112015023523B8 (pt) 2013-03-15 2023-03-07 Merck Sharp & Dohme Composições farmacêuticas e recipiente de forma de dosagem única
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
FR3018812A1 (fr) 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
US10548911B2 (en) 2014-06-16 2020-02-04 University Of Rochester Small molecule anti-scarring agents
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102419769B1 (ko) * 2016-08-11 2022-07-13 아다미스 파마슈티칼스 코포레이션 약물 조성물
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
US11370775B2 (en) * 2016-09-14 2022-06-28 Yufeng Jane Tseng Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
CN110317164B (zh) * 2019-07-06 2022-08-19 抚州三和医药化工有限公司 一种奥美拉唑中间体的制备方法
EP4284374A1 (en) 2021-01-29 2023-12-06 Abbvie Inc. Methods of administrating elagolix
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234058A (ru) * 1968-10-21 1971-06-03
SE418966B (sv) * 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
US4045564A (en) * 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IN148930B (ru) * 1977-09-19 1981-07-25 Hoffmann La Roche

Also Published As

Publication number Publication date
JPS58192880A (ja) 1983-11-10
JPS54141783A (en) 1979-11-05
AT389995B (de) 1990-02-26
EP0005129B1 (en) 1981-04-29
CS254979A2 (en) 1988-07-15
NO1994027I1 (no) 1994-12-21
FI65067C (fi) 1984-03-12
NL930074I2 (nl) 1994-02-16
AU4602779A (en) 1979-10-18
NO152216B (no) 1985-05-13
US4508905A (en) 1985-04-02
NO152785B (no) 1985-08-12
ATA273279A (de) 1983-09-15
NO1995005I1 (no) 1995-06-14
SU895292A3 (ru) 1981-12-30
CA1127158A (en) 1982-07-06
CY1232A (en) 1984-06-29
IE48370B1 (en) 1984-12-26
NL930074I1 (nl) 1993-09-16
NZ190203A (en) 1984-03-16
DE2960293D1 (en) 1981-08-06
MY8500074A (en) 1985-12-31
DK151179A (da) 1979-10-15
SU873880A3 (ru) 1981-10-15
NL930075I1 (nl) 1993-09-16
NL930075I2 (nl) 1994-02-16
FI65067B (fi) 1983-11-30
HU179022B (en) 1982-08-28
AU529654B2 (en) 1983-06-16
ZA791586B (en) 1980-04-30
FI791219A (fi) 1979-10-15
SU878196A3 (ru) 1981-10-30
US4337257A (en) 1982-06-29
IE790785L (en) 1979-10-14
US4255431A (en) 1981-03-10
CS261851B2 (en) 1989-02-10
NO840112L (no) 1979-10-16
BG61492B2 (bg) 1997-09-30
SE7804231L (sv) 1979-10-15
DD142882A5 (de) 1980-07-16
AT374471B (de) 1984-04-25
NO1995006I1 (no) 1995-06-14
EP0005129A1 (en) 1979-10-31
ATA290483A (de) 1989-08-15
LT2274B (lt) 1993-12-15
JPS6353191B2 (ru) 1988-10-21
LU88305I2 (fr) 1994-05-04
DK150510C (da) 1987-12-07
HK15284A (en) 1984-03-02
DK150510B (da) 1987-03-16
SG63383G (en) 1984-07-27
NO791227L (no) 1979-10-16
NO152216C (no) 1985-08-21
NO152785C (no) 1985-11-20
JPS6034956B2 (ja) 1985-08-12
LU88307I2 (fr) 1994-05-04

Similar Documents

Publication Publication Date Title
SU873879A3 (ru) Способ получени производных бензимидазола или их солей
SU795476A3 (ru) Способ получени производныхбЕНзиМидАзОлА или иХ СОлЕй
SU509221A3 (ru) Способ получени 1,4-дигидро-пиридинов или их солей
SU727142A3 (ru) Способ получени замещенных 1-сульфонилбензимидазолов
RU2163238C2 (ru) Способ получения магниевой соли замещенного сульфинил-гетероциклического соединения
SU537626A3 (ru) Способ получени производных алканоламина
SU1153829A3 (ru) Способ получени 2-гуанидино-4-имидазотиазолов или их фармацевтически приемлемых аддитивных солей кислот
PL132249B1 (en) Process for preparing novel derivatives of 2,4-dihydroxyhex-5-en-1-carboxylic acid
EP0181846B1 (en) New substituted benzimidazoles, a process for their preparation and their use for inhibiting gastric acid secretion
SU873872A3 (ru) Способ получени производных аминопропанола или их солей
NO159932B (no) Fremgangsmaate for fremstilling av substituerte imidazolyl-tiazol-derivater.
CS274460B2 (en) Method of 1-cyclopropyl-7-substituted-6-fluor-4-oxo-1,4-dihydroquinoline-3-carboxylic acid's derivatives production
EP0116628B1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
SU1222196A3 (ru) Способ получени производных 2-аминометил-5-тиометилфурана
SU492076A3 (ru) Способ получени замещенных гуанидина
SU656521A3 (ru) Способ получени производных тиено(3,2-с) пиридина или их солей
SU1258325A3 (ru) Способ получени производных @ -фталидил-5-фторурацила
SU795487A3 (ru) Способ получени производных геллебри-гЕНиНА или иХ СОлЕй
EP1476441A1 (en) A method of eliminating sulfone analog in the synthesis of pyridine-benzimidazole sulfoxides
SU1311621A3 (ru) Способ получени 2-гуанидино-4-триазолил-тиазолов
SU683624A3 (ru) Способ получени производных тиено-(3,2-с)пиридина или их солей
KR910008938B1 (ko) 피리딘 유도체의 제조방법
US2469554A (en) The process of preparing the lactone of 2 methyl 3 hydroxy 4 carboxy 5 hydroxymethyl pyridine
US2568809A (en) Tetrahalomethylhexestrols and derivatives thereof
EP0535528A1 (en) Antibacterial 5-Nitro-1-methyl-imidazolyl-3-terbutyl-2-hydroxy-aryl-carbinols